Department of Experimental and Clinical Biomedical Sciences "M Serio", University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X.
Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.
新型乳腺癌全身治疗药物正在迅速应用于临床实践。与传统化疗相比，这些药物的作用机制和不良反应谱往往不同。因此，针对正在研究的全身治疗药物进行的改变临床实践的临床试验的基础数据较少，而关于放疗的数据则更为稀少。将这些新的全身治疗药物与放疗结合起来具有挑战性。鉴于乳腺癌多模式管理的快速变革，多学科团队必须团结起来，确保所有患者都能获得最佳、安全和公平的治疗。本协作组由放射治疗、临床肿瘤学和医学肿瘤学家、基础和转化科学家以及患者权益倡导者组成，旨在：对将新型药物与乳腺癌放疗相结合的文献进行评估、综合和总结；在缺乏特定证据的情况下，就药物与放疗的整合问题达成共识声明；为随后测试新型药物的研究记录放疗数据和保证质量提出最佳实践建议。
